National Health Investors Inc

NHI remains in a Stage 4 declining regime with price below all major EMAs and SMAs and the primary Support Failure pattern confirming bearish medium-term asymmetry. Short- and long-term trends are down, and rallies into the falling 9-EMA and 21-EMA have been consistently rejected. While the RSI is approaching oversold, there is no sign of a sustained reversal, so the optimal approach is to initiate short exposure now in the resistance area around the short-term EMAs.

• ↑SHOP to 40-50% portfolio, targeting 8-9% NOI growth H2
• ↑EPS guidance $4.74-$4.79 vs consensus $4.87, upside potential
• ↓Q2 FFO flat at $1.19/share; net income boosted by $22M sales